Table 2. Episode characteristics.
| Variables | No. of episodes (%) | ||
|---|---|---|---|
| Classification of sepsis severity | |||
| Severe sepsis | 42 (25) | ||
| Septic shock | 129 (75) | ||
| Classification of sepsis | |||
| Clinically-documented infection | 55 (32) | ||
| Microbiologically-documented infection | 116 (68) | ||
| Febrile neutropenia | 55 (32) | ||
| Primary origin of sepsis | |||
| Lung | 74 (43) | ||
| Abdomen | 19 (11) | ||
| Urinary | 10 (6) | ||
| Soft tissue | 2 (1) | ||
| Catheter-related bloodstream infection | 8 (5) | ||
| Hepatobiliary | 12 (7) | ||
| Mixed | 15 (9) | ||
| Other | 5 (3) | ||
| Microbiological documentation | |||
| Gram-positive bacteria | 48 (28) | ||
| Staphylococcus aureus | 19 (11) | ||
| Streptococcus pneumoniae | 5 (3) | ||
| Staphylococcus spp. | 5 (3) | ||
| Streptococcus spp. | 3 (2) | ||
| Enterococcus spp. | 15 (9) | ||
| Other | 1 (1) | ||
| Gram-negative bacteria | 92 (54) | ||
| Klebsiella spp. | 30 (18) | ||
| Escherichia coli | 25 (15) | ||
| Pseudomonas aeruginosa | 13 (8) | ||
| Stenotrophomonas maltophilia | 9 (5) | ||
| Acinetobacter baumannii | 7 (4) | ||
| Enterobacter cloacae | 4 (2) | ||
| Other | 4 (2) | ||
| Fungi | 9 (5) | ||
| Candida spp. | 8 (5) | ||
| Cryptococcus neoformans | 1 (1) | ||
| Pneumocystis jirovecii | 1 (1) | ||
| Tuberculosis | 2 (1) | ||
| Combined | 29 (17) | ||
| Unknown | 55 (32) | ||
| Antibiotic therapy | |||
| Monotherapy | 20 (12) | ||
| Combination therapy | 151 (88) | ||
| Antifungal therapy | 38 (22) | ||
| Outcomes within 7 days | |||
| Success without modification | 76 (44) | ||
| Success with modification | 29 (17) | ||
| Treatment failure | 66 (39) | ||
| Outcomes | |||
| 28-day mortality | 45 (29) | ||
| ICU mortality | 37 (24) | ||
| Hospital mortality | 58 (37) | ||
| ICU-free days | 18.2 (0–23.8)* | ||
| Length of stay in ICU (days) | 6.1 (3.2–11.0)* | ||
| Length of stay in hospital (days) | 28.8 (14.9–51.1)* |
ICU intensive care unit;
*Continuous variables are summarized as a median and the interquartile range.